The immune-modulating effects of anesthetics in vitro were first demonstrated more than 100 years ago [
7]. The increasing knowledge of recent years is strongly related to developments in basic science and improvements in laboratory technique, e. g., cell separation and cell culture methods. It has been demonstrated that, at concentrations used clinically, different anesthetics depress the functions of the inflammatory response differentially.
Ketamine
Ketamine, an
N-methyl-d-aspartate (NMDA)-receptor antagonist, acts at different levels of inflammation, interacting with inflammatory cell recruitment, cytokine production, and regulation of inflammatory mediators [
11]. The immune-inhibitory effects of ketamine were recently found to be partly due to inhibition of transcription factor activator protein-1 and nuclear factor-kappa B (NF-κB), which regulate the production of several proinflammatory mediators [
12]. The notion that ketamine interferes with immunity comes from the early observations of improved outcomes in critically ill patients and in experimental septic shock [
13]. In vivo, a sub-anesthetic dose of ketamine produced a dose-dependent decrease in mortality with a significant reduction in production of TNF-α and IL-6 in septic rats [
11,
14]. Intravenous administration of ketamine abolished albumin extravasation in a rat model of chemical peritonitis [
14]. In other studies, anesthetic doses of ketamine attenuated lipopolysaccharide (LPS)-induced liver injury, with a reduction in cyclooxygenase (COX)-2, inducible nitric oxide synthase (iNOS), and NF-κB-binding activity [
11,
14]. These data clearly indicate that ketamine may exert anti-inflammatory actions in vivo. These anti-inflammatory effects have also been found in clinical settings. Low-dose ketamine (0.25–0.5 mg/kg) significantly suppressed intraoperative and postoperative increases in serum IL-6 and C-reactive protein (CRP) in patients undergoing coronary artery bypass graft (CABG) surgery with cardiopulmonary bypass (CPB) [
11,
14] and significantly decreased superoxide production. However, low-dose ketamine was not shown to have any anti-inflammatory effects in low-risk patients undergoing off-pump CABG. The link remains controversial [
14].
Midazolam
Midazolam, a widely used benzodiazepine derivative, acts on GABA receptors by increasing neuronal permeability to chloride ions, leading to cell hyperpolarization. It is known to inhibit certain aspects of immune function [
15]. Midazolam binds to peripheral receptors on macrophages and modulates their metabolic oxidative responsiveness in vitro. It has been suggested that clonazepam also binds to receptors on macrophages and inhibits their capacity to produce IL-1, IL-6, and TNF-α in a T-cell independent manner [
16]; however, it was ineffective. These results demonstrate an in vivo immunosuppressive property of peripheral and mixed benzodiazepine receptor agonists (midazolam and diazepam) but not central-type receptor agonists (clonazepam), affecting characteristic phagocyte functions involved in host-defense mechanisms as well as in the inflammatory response [
15]. Midazolam is also able to inhibit human neutrophil function and the activation of mast cells induced by TNF-α in vitro, and suppresses expression of IL-6 mRNA in human blood mononuclear cells [
17]. When administered to LPS-stimulated macrophages, midazolam suppressed the respiratory burst of reactive oxygen species (ROS), inhibited NF-κB activation via suppression of IκB-α degradation, and inhibited p38 activation, which has been reported to play a critical role in LPS-mediated COX-2 and iNOS expression, pathways involved in the proinflammatory macrophage phenotype [
18]. Nonetheless, midazolam infusion did not affect cytokine production in septic patients [
15].
Propofol
Propofol, another GABA receptor agonist, has been shown to impair several monocyte and neutrophil functions of the innate immune system, including respiratory burst [
19], chemotaxis [
20], phagocytosis [
21] and polarization [
4]. While some authors have showed that the inhibitory properties on human neutrophils and complement activation of propofol are related to its lipid carrier vehicle [
4,
22], others have suggested that propofol at least partly inhibits human neutrophil chemotaxis by suppressing the p44/42 mitogen-activated protein kinase (MAPK) pathway [
4,
20]. In clinically relevant concentrations, propofol inhibits the production of a chemotactic agent in human neutrophils [
4,
20]. The proliferative-suppressing effects of propofol were only observed in polymorphonuclear leukocytes (PMNs) obtained from critically ill patients who were primarily immunosuppressed [
23]. Lymphocyte proliferation [
4] and cytokine release in response to endotoxin were not found to be impaired in whole blood culture medium obtained from healthy volunteers [
4,
24]. In an animal model of endotoxin-induced lung injury, propofol had anti-inflammatory effects. The underlying molecular mechanisms are still unclear; however, propofol is not known to inhibit activation of NF-κB [
4]. Recent data suggest that propofol produces only cell-mediated immunomodulatory effects on innate immunity, and that these effects might be generated by its lipid solvent [
4].
Opioids
The link between opioid use and alterations in host immune function is often mentioned in the literature, and has been formally documented since the early 19
th century. The increased incidence of various local and systemic infections in intravenous drug abusers led to the conclusion that the causative link between drug use and infections could not be simply explained by the injection process, but that opiates themselves were acting to modulate immune function [
25]. Different opioids affect immune function differently depending on drug factors, host factors, and the duration of exposure [
26]. Morphine, fentanyl, remifentanil, methadone and codeine present strong immunomodulatory effects, while tramadol, hydrocodone, oxycodone, and buprenorphine present much weaker or no immune-modulating capacity [
25]. This feature of opioids is often linked to central neuro-endocrine/neuro-paracrine and peripheral mechanisms and to peripheral actions mediated by mu-opioid receptors on immune cells [
25].
The importance of centrally mediated mechanisms is supported further by the observation that opioids that cross the blood brain barrier (BBB) exert more immunomodulatory effects than opioids that do not cross the BBB [
27]. Although opioid effects are largely attributed to decreased central sympathetic nervous system outflow, opioids can also cause direct sympathetic nervous activation, which may suppress the proliferation and function of some immune cell populations and primary and secondary lymphoid tissues [
28]. The interaction of opioids with the HPA axis and its components (ACTH and cortisol production) is complex, species- and time-dependent, with different effects after acute and chronic administration. In humans, data are scarce; however, current evidence suggests that acute administration of opioids results in either a reduction or no change in ACTH or glucocorticoids. There is evidence that opioids attenuate the circadian rhythm of ACTH and cortisol, leading to consistent increments in circulating levels of these hormones, which might be sufficient to produce immune suppression [
25].
Several studies have suggested that mu-opioid receptors are expressed on peripheral blood mononuclear cells [
4,
29,
30]; however, in contrast to previous reports and despite using several validated methodologies, a recent investigation was unable to detect any opioid receptors or transcripts in mononuclear cells collected from venous blood [
25].
There are well-documented, dose-dependent, immunosuppressive effects of morphine, which is known to impair monocyte and neutrophil function, NK cell-mediated cytotoxicity, lymphocyte and macrophage proliferation and cytokine release. Morphine promotes apoptosis by direct activation of the enzymes involved in cell apoptosis, inhibits leukocyte function by increasing intracellular concentrations of NO and cyclic AMP, and by inhibiting nuclear NF-κB via NO-dependent mechanisms [
4]. Recent studies of the effects of synthetic opioids used in general anesthesia showed no more than transient immunomodulatory changes [
1,
2,
4].
Fentanyl is known to enhance NK-cell cytotoxicity and increase NK and cytotoxic (CD8+) cell counts; however, the production of superoxide by PMNs and the number of circulating B- and T-lymphocytes remained unchanged in healthy volunteers [
4,
31]. These effects of fentanyl on NK cells seem to be more centrally mediated, as fentanyl does not affect NK-cell activity directly. In two studies, sufentanil and alfentanil were observed to produce inhibitory effects on leukocyte migration, NK-cell activity, and mitogen-induced lymphocyte proliferation [
1,
2,
4,
32].
Thiopental
When administered over prolonged periods, short- and intermediate-acting barbiturates, which act as GABA receptor agonists, may induce iatrogenic immunosuppression. A higher incidence of infections has been described in head-injured patients with increased intracranial pressure (ICP) who received prolonged infusions of thiopental [
4,
33]. Thiopental is one of the most investigated anesthetic agents and is widely used for the induction of general anesthesia. Its inhibitory effects on the non-specific immune system have been well documented in several studies. In clinically used concentrations, thiopental has been shown to inhibit the bactericidal functions of leukocytes; neutrophil polarization, chemotaxis, adherence, phagocytosis, and respiratory burst; and monocyte chemotaxis [
2]. In high concentrations, thiopental affects neutrophil and monocyte phagocytosis. In short, the described inhibitory effects of thiopental are indicative of direct cell-mediated inhibition of the immune response and a strong anti-inflammatory effect. In addition, thiopental is known to depress mitogen/antigen-induced lymphocyte proliferation in different culture mediums, and decreases the quantity of cytokines released in response to mitogens or endotoxins [
34]. Recent studies have suggested that thiopental inhibits NF-κB activation [
4]. Clinically, the immunosuppressive effects of thiopental are probably of minor clinical relevance, since it is often used only for induction of anesthesia [
20].
Dexmedetomidine
Dexmedetomidine, an agonist of α
2-adrenergic receptors in certain regions of the brain, has been shown to reduce proinflammatory cytokine levels in experimental sepsis [
35] as well as in critically ill [
1,
4] and postoperative patients [
36]. A significant decrease in leukocyte counts, CRP, IL-6, IL-8 and TNF-α levels in dexmedetomidine-treated patients is indicative of its anti-inflammatory potential when used as a perioperative adjunct [
1,
2,
4]. A number of mechanisms of action have been postulated for dexmedetomidine, including: modulation of cytokine production by macrophages/monocytes during the stress response, which may also be stimulated via α2-adrenoceptors; inhibition of apoptosis; central sympatholytic effects, including stimulation of cholinergic anti-inflammatory pathways; and antinociceptive action involving interactions between pain and immune factors (proinflammatory cytokines) [
1,
2,
4]. So far, however, these mechanisms remain unclear [
37].
Volatile anesthetics
Inhalational anesthetic agents have inhibitory effects on neutrophil function, decrease lymphocyte proliferation, and suppress cytokine release from peripheral blood mononuclear cells [
1,
2,
38]. Halogenated anesthetics are known to suppress inflammatory cytokines in rat alveolar cells [
4]. In contrast, exposure to volatile anesthetics and mechanical ventilation has been shown to induce increased gene expression of proinflammatory cytokines [
38]. Volatile anesthetics affect the expression of iNOS by reversible inhibition of voltage-dependent calcium channels and decreased intracellular calcium concentrations. Thus, the in vitro effects of volatile anesthetics predominantly consist of inhibition of immune products, but these are generally transient, as well as dose- and time-dependent [
1,
4,
38].
Sevoflurane
Anesthetic preconditioning to sevoflurane has been shown to promote protection from endotoxemia, ischemia–reperfusion injury, myocardial ischemia–reperfusion injury, among other disease models. Sevoflurane attenuated the activation of NF-κB and subsequent expression of NF-κB-dependent inflammatory mediators via Toll-like receptors (TLRs) [
38]. Additionally, sevoflurane protects against vascular endothelium dysfunction induced by oxidative stress and inflammation through activation of the eNOS/NO pathway and inhibition of NF-κB. Endothelial dysfunction induced by oxidative stress and inflammation plays a critical role in the pathogenesis of cardiovascular diseases [
37]. In particular, sevoflurane has been shown to induce a more pronounced suppression of cytokine release than isoflurane or enflurane.
Isoflurane
Isoflurane exposure leads to reduction in leukocyte counts and levels of systemic proinflammatory cytokines (TNF-α, IL-6 and IL-1β), as well as less macrophage activation and polarization toward the M2 phenotype. These effects were found to be protein kinase C-dependent and also due to systemic inhibition of NF-κB [
38]. These findings suggest that pre-exposure to volatile anesthetics induces a systemic anti-inflammatory effect. On the other hand, exposure to isoflurane has been shown to lead to cognitive impairment and a small increase in IL-1β and activated caspase-3 levels in the hippocampi of both young adult and elderly rats. These results suggest that isoflurane induces neuroinflammation, which then leads to cognitive impairment.
Little is known regarding the mechanisms of volatile anesthetic-induced neuroinflammation, but isoflurane has been shown to open the BBB, increasing the permeation of intravascular substances into brain tissue. A recent study showed that exposure of H4 human neuroglioma cells to 2% isoflurane for 6 h activated NF-κB, increasing inflammatory cytokine production. Therefore, local activation of NF-κB is presumably a mechanism for isoflurane-induced neuroinflammation [
39].